Indaptus Therapeutics is a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, which Co. refers to as the Accordion Pill. Co.'s primary product candidate, Accordion Pill Carbidopa/Levodopa is being developed for the indication of treatment of Parkinson's disease symptoms in Parkinson's disease patients. In addition, Co. has initiated a clinical development program for its Accordion Pill platform with the two primary cannabinoids contained in cannabis sativa, which it refers to as AP-Cannabinoids. Co. is formulating and testing Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various pain indications. The INDP average annual return since 2015 is shown above.
The Average Annual Return on the INDP average annual return since 2015 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether INDP average annual return since 2015 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the INDP average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|